Biotech MannKind (MNKD 2.45%), which is developing the inhalable insulin product Afrezza, released its third-quarter earnings report after the market closed on Thursday. There were several key updates regarding the company's financial situation and cash burn.

In the following video, health-care analysts Max Macaluso and David Williamson discuss these results and a few issues investors need to watch.